For illustrative purposes only. Not actual patient data.
Explore what LibreView* can do for you and your care team.
Turn diabetes care into a more informed team effort for shared*† decision making. Patients will have a better understanding of their recommended treatment, and you’ll have reports to help fill in the blanks between visits1,2.
LibreView reports include:
Ambulatory Glucose Profile (AGP) Report:
Includes glucose statistics and targets, time in range (TIR), AGP, and daily glucose profiles.
The AGP report with TIR aligns with the International Consensus on TIR standards3.
For illustrative purposes only. Not actual patient data.
For illustrative purposes only. Not actual patient data.
Daily Patterns Report:
Shows average glucose levels, carbohydrate intake data, and insulin administration data during the reporting period.
For illustrative purposes only. Not actual patient data.
For illustrative purposes only. Not actual patient data.
* The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.
† Check www.librelinkup.com for information about mobile device and operating system compatibility. LibreLinkUp is not intended to be used for dosing decisions or to replace self-monitoring practices as advised by a physician, and requires registration with LibreView.
‡ Default range is 70–180 mg/dL. Consult with a healthcare professional on individual target glucose range.
References: 1. Unger, Jeff, Pamela Kushner, and John E. Anderson. "Practical guidance for using the FreeStyle Libre flash continuous glucose monitoring in primary care." Postgraduate Medicine 132, no. 4 (2020): 305–313. https://doi.org/10.1080/00325481.2020.1744393. 2. Huang, Eileen, Mohamed Nada, and Eugene Wright, Jr. "73–LB: Ambulatory Glucose Profile Informs Better Treatment Decisions for Type 2 Basal-Insulin Patients." Diabetes 71, no. Supplement_1 (2022): 73–LB. https://doi.org/10.2337/db22-73-LB. 3. Battelino, Tadej, et al. "Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on Time in Range." Diabetes Care 42, no. 8 (2019): 1593–1603. https://doi.org/10.2337/dci19-0028.
ADC-52574 v3.0
Important Safety Information
Failure to use FreeStyle Libre systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose reading and alarms (if enabled) do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Get medical attention when appropriate. Abbott Customer Service: 855-632-8658 or visit FreeStyleLibre.us for safety info.
The product images are for illustrative purposes only.
The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without prior written authorization of Abbott Laboratories, except to identify the product or services of the company.
This website and the information contained herein is intended for use by residents of the United States.
ADC-45115 v21.0
